|32.02 1.81 (5.99%)||12-01 16:00|
|Targets||6-month :||39.18||1-year :||45.76|
|Resists||First :||33.54||Second :||39.18|
|Supports||First :||26.48||Second :||22.11|
|MAs||MA(5) :||29.78||MA(20) :||28.22|
|MA(100) :||28.97||MA(250) :||34.79|
|MACD||MACD :||1||Signal :||0.7|
|%K %D||K(14,3) :||94.7||D(3) :||78.4|
|52-week||High :||48.4||Low :||22.11|
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ CLDX ] has closed above the upper band by 17.8%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 5.5% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
|If tomorrow:||Open lower||Open higher|
|High:||30.28 - 30.39||30.39 - 30.48|
|Low:||29.04 - 29.18||29.18 - 29.29|
|Close:||30 - 30.22||30.22 - 30.39|
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company's proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation. The company has research collaboration and license agreements with University of Southampton to develop human antibodies towards CD27; Amgen Inc. with exclusive rights to CDX-301 and CD40 ligand; and Yale University. Celldex Therapeutics, Inc. was incorporated in 1983 and is headquartered in Hampton, New Jersey.
|Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
|Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
|Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
|Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
|Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
|Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
|Shares Out||0 (M)|
|Shares Float||55 (M)|
|Held by Insiders||4.102e+007 (%)|
|Held by Institutions||0.3 (%)|
|Shares Short||5,760 (K)|
|Shares Short P.Month||0 (K)|
|EPS Est Next Qtrly||0|
|EPS Est This Year||0|
|EPS Est Next Year||0|
|Book Value (p.s.)||0|
|Profit Margin||0 %|
|Operating Margin||-2 %|
|Return on Assets (ttm)||718.4 %|
|Return on Equity (ttm)||-26 %|
|Qtrly Rev. Growth||4.37e+006 %|
|Gross Profit (p.s.)||132.37|
|Sales Per Share||-20.44|
|Qtrly Earnings Growth||-2.7 %|
|Operating Cash Flow||0 (M)|
|Levered Free Cash Flow||-97 (M)|
|Price to Book value||0|
|Price to Sales||-1.57|
|Price to Cash Flow||12.63|
|Dividend Pay Date||Invalid DateTime.|
|Ex-Dividend Date||Invalid DateTime.|